MCID: DRM011
MIFTS: 48

Dermatophytosis

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Dermatophytosis

MalaCards integrated aliases for Dermatophytosis:

Name: Dermatophytosis 12 72 14 69
Tinea 69

Classifications:



External Ids:

Disease Ontology 12 DOID:8913
ICD10 32 B35 B35.9
ICD9CM 34 110 110.9
NCIt 46 C26745

Summaries for Dermatophytosis

Disease Ontology : 12 A cutaneous mycosis that results_in fungal infection located in scalp, located in glabrous skin, or located in nail, has material basis in Ascomycota fungi that belong to a group called dermatophytes, which have the ability to utilize keratin as a nutrient source.

MalaCards based summary : Dermatophytosis, also known as tinea, is related to tinea corporis and tinea cruris, and has symptoms including pruritus, fever and exanthema. An important gene associated with Dermatophytosis is CARD9 (Caspase Recruitment Domain Family Member 9), and among its related pathways/superpathways is GPCRs, Class B Secretin-like. The drugs Ketoconazole and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include scalp, glabrous skin and nail.

CDC : 3 Ringworm poster: Protect Yourself From Itchy Rashes [PDF – 1 page]

Wikipedia : 72 Dermatophytosis, also known as ringworm, is a fungal infection of the skin. Typically it results in a... more...

Related Diseases for Dermatophytosis

Diseases related to Dermatophytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 99)
# Related Disease Score Top Affiliating Genes
1 tinea corporis 32.9 DEFB4A SQLE
2 tinea cruris 32.8 DEFB4A SQLE
3 tinea capitis 31.4 CARD9 FLNC KATNAL2 SLC7A1
4 candidiasis 29.8 CARD9 DEFB4A
5 deep dermatophytosis 12.4
6 tinea pedis 11.8
7 tinea unguium 11.7
8 tinea manuum 11.7
9 tinea barbae 11.5
10 tinea profunda 11.0
11 dermatomycosis 10.9
12 candidiasis, familial, 2 10.8
13 tinea imbricata 10.4
14 oral candidiasis 10.2 DEFB4A LTF
15 gingivitis 10.0 DEFB4A LTF
16 chronic mucocutaneous candidiasis 9.9
17 tinea favosa 9.9
18 kerion celsi 9.9
19 blood group, i system 9.8
20 aging 9.8
21 allergic hypersensitivity disease 9.8
22 urticaria 9.8
23 dermatitis 9.8
24 pustulosis of palm and sole 9.8
25 psoriasis 9.8
26 pemphigus 9.8
27 opportunistic mycosis 9.8 CARD9 FLNC
28 keratitis, hereditary 9.8
29 mungan syndrome 9.8
30 erythema multiforme 9.8
31 lymphoma 9.8
32 sarcoma 9.8
33 ichthyosis 9.8
34 acquired immunodeficiency syndrome 9.8
35 ige responsiveness, atopic 9.6
36 kaposi sarcoma 9.6
37 systemic lupus erythematosus 9.6
38 nevus anemicus 9.6
39 ovalocytosis, southeast asian 9.6
40 rheumatoid arthritis 9.6
41 schistosoma mansoni infection, susceptibility/ 9.6
42 pituitary adenoma 4, acth-secreting 9.6
43 hemochromatosis, type 1 9.6
44 leprosy 3 9.6
45 myasthenia gravis 9.6
46 mycosis fungoides 9.6
47 branchiootic syndrome 1 9.6
48 dermatitis, atopic 9.6
49 langerhans cell histiocytosis 9.6
50 mycobacterium tuberculosis 1 9.6

Comorbidity relations with Dermatophytosis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Ischemic Heart Disease

Graphical network of the top 20 diseases related to Dermatophytosis:



Diseases related to Dermatophytosis

Symptoms & Phenotypes for Dermatophytosis

UMLS symptoms related to Dermatophytosis:


pruritus, fever, exanthema

Drugs & Therapeutics for Dermatophytosis

Drugs for Dermatophytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketoconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65277-42-1 3823 47576
2
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4
Bifonazole Approved, Investigational Phase 4,Phase 3,Phase 2 60628-96-8 2378
5
Terbinafine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 91161-71-6 1549008 5402
6
Ciclopirox Approved, Investigational Phase 4,Phase 3,Phase 2 29342-05-0 2749
7
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 2 84625-61-6 55283
8
Naftifine Approved Phase 4,Phase 3,Phase 2,Phase 1 65472-88-0 47641 73342
9
Tavaborole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 174671-46-6
10
Efinaconazole Approved Phase 4,Phase 3 164650-44-6
11 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
12 Gastrointestinal Agents Phase 4,Phase 3
13 Amorolfine Phase 4,Phase 3,Phase 2,Phase 1
14 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
15 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
16 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
17 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
18 Dermatologic Agents Phase 4
19 Hormones Phase 4,Phase 3,Phase 2,Phase 1
20 Antacids Phase 4
21 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
22 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
23 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Keratolytic Agents Phase 4
26 Anti-Ulcer Agents Phase 4
27 Proton pump inhibitors Phase 4
28 Hydroxyitraconazole Phase 4,Phase 3,Phase 2
29
Clotrimazole Approved, Vet_approved Phase 3,Phase 1 23593-75-1 2812
30
Econazole Approved Phase 3,Phase 2 27220-47-9 3198
31
Tolnaftate Approved, Investigational, Vet_approved Phase 3 2398-96-1 5510
32
Sertaconazole Approved, Investigational Phase 3 99592-32-2 65863
33
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
34
Griseofulvin Approved, Investigational, Vet_approved Phase 3 126-07-8 441140
35
Albendazole Approved, Vet_approved Phase 2, Phase 3 54965-21-8 2082
36
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
37
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
38 Papaya Approved, Nutraceutical Phase 2, Phase 3
39 Respiratory System Agents Phase 3,Phase 2
40 Micronutrients Phase 2, Phase 3
41 Trace Elements Phase 2, Phase 3
42 Anthelmintics Phase 2, Phase 3
43 Peripheral Nervous System Agents Phase 3,Phase 2
44 Anti-Asthmatic Agents Phase 3,Phase 2
45 Anti-Inflammatory Agents Phase 3,Phase 2
46 Antimitotic Agents Phase 2, Phase 3
47 Antiprotozoal Agents Phase 2, Phase 3
48 Antiparasitic Agents Phase 2, Phase 3
49 Autonomic Agents Phase 3,Phase 2
50 Betamethasone Valerate Phase 3 2152-44-5

Interventional clinical trials:

(show top 50) (show all 191)

# Name Status NCT ID Phase Drugs
1 Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris Unknown status NCT02394340 Phase 4 Omeprazole 40mg
2 Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Unknown status NCT02436291 Phase 4
3 Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
4 An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis Completed NCT02466867 Phase 4 Naftin® Cream, 2% (younger pediatric cohort);Naftin® Cream, 2% (older pediatric cohort)
5 Pediatric Subjects With Tinea Corporis Completed NCT02227290 Phase 4 Naftin Cream;Placebo Cream
6 Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris Completed NCT02767271 Phase 4 Luliconazole Cream 1%
7 Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis Completed NCT01712360 Phase 4 NAFT500 (pediatric);NAFT600 (pediatric);NAFT500 (adult);NAFT600 (adult)
8 Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis Completed NCT02767947 Phase 4 Luliconazole Cream 1%;Vehicle Cream
9 Ketoconazole Foam 2% for the Treatment of Versicolor Completed NCT00830388 Phase 4 Ketoconazole 2% Foam
10 An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents Completed NCT03405818 Phase 4 Tavaborole 5% Topical Solution
11 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1% Completed NCT02705664 Phase 4 Loceryl Nail Lacquer;Urea Ointment;Bifonazole Cream
12 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Completed NCT02679911 Phase 4 Loceryl Nail Lacquer;Ciclopirox Nail Lacquer
13 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
14 Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish Completed NCT02321098 Phase 4 Loceryl Nail Lacquer;Loceryl Nail Lacquer;Loceryl Nail Lacquer follow up period
15 Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis Completed NCT01851590 Phase 4 Amorolfine;Terbinafine
16 Topical Penlac Nail Lacquer for Onychomycosis in Children Completed NCT01419847 Phase 4 Ciclopirox;Placebo
17 Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4 Itraconazole
18 Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis Recruiting NCT02812771 Phase 4 Efinaconazole
19 Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis Recruiting NCT02812043 Phase 4 Amorolfine
20 Study Evaluating the Effect of Jublia on Dermatophytomas Active, not recruiting NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
21 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish Active, not recruiting NCT03110029 Phase 4 Efinaconazole 10% (Jublia)
22 Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis Not yet recruiting NCT03280927 Phase 4 Jublia®
23 Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children Terminated NCT01646580 Phase 4 ciclopirox
24 Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females Unknown status NCT00856596 Phase 3 Sertaconazole nitrate cream 2%
25 Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Unknown status NCT01105013 Phase 3 Clotrimazole
26 TDT 067 Onychomycosis Study Unknown status NCT01145807 Phase 3 TDT067;Placebo;Transfersome
27 Treating Onychomychosis Unknown status NCT00776464 Phase 2, Phase 3
28 Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01289015 Phase 3 NAFT-600 ( naftin 2 % gel );Placebo
29 Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01290341 Phase 3 NAFT-600 (naftin 2 % gel);Placebo
30 Topical Antifungal Treatment for Tinea Cruris Completed NCT01342315 Phase 3 33525;Placebo
31 Topical Antifungal Treatment for Tinea Pedis Completed NCT01396811 Phase 3 33525;Placebo
32 Topical Antifungal Treatment for Tinea Pedis Completed NCT01396785 Phase 3 33525;Placebo
33 Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis Completed NCT01349998 Phase 3 Product 33525
34 Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis Completed NCT01433107 Phase 3 Terbinafine;Terbinafine Placebo
35 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117767 Phase 3 Terbinafine hydrochloride (HCl);Griseofulvin
36 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117754 Phase 3 Terbinafine hydrochloride
37 Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis Completed NCT00802672 Phase 3 Ciclopirox Olamine Cream;Loprox Cream 0.77%;Placebo
38 Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis Completed NCT03129321 Phase 3 Econazole Nitrate Cream, 1%;Placebo
39 Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris Completed NCT01885156 Phase 3 Naftin 1% Cream;Placebo Cream
40 Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis Completed NCT00750139 Phase 3 NAFT-500;Placebo 2-weeks;Naftin 1%;Placebo 4-weeks
41 Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris Completed NCT00750152 Phase 3 NAFT-500;Placebo
42 Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis Completed NCT01353976 Phase 3 Econazole Nitrate Foam 1%
43 Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis Completed NCT01358240 Phase 3 Econazole Nitrate Foam 1%;Vehicle Foam;Econazole Nitrate Cream 1%
44 A Study Of Diflucan In Children With Ringworm Of The Scalp Completed NCT00645242 Phase 3 fluconazole
45 BE Study of Naftifine HCL Completed NCT02633813 Phase 3 Naftifine hydrochloride 2%;Placebo;Naftin® 2% (Naftifine hydrochloride 2%)
46 Design and Clinical Evaluation of a School Meal With Deworming Properties Completed NCT02725255 Phase 2, Phase 3 Albendazole
47 Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Completed NCT01302119 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
48 Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Completed NCT01270971 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
49 Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00459537 Phase 3 terbinafine hydrogen chloride;amorolfine nail lacquer
50 Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail Completed NCT00443898 Phase 3 terbinafine;Placebo;terbinafine;Placebo

Search NIH Clinical Center for Dermatophytosis

Genetic Tests for Dermatophytosis

Anatomical Context for Dermatophytosis

The Foundational Model of Anatomy Ontology organs/tissues related to Dermatophytosis:

18
Scalp, Glabrous Skin, Nail

MalaCards organs/tissues related to Dermatophytosis:

38
Skin, Testes, T Cells, Thymus, Monocytes, Lymph Node, Liver

Publications for Dermatophytosis

Articles related to Dermatophytosis:

(show top 50) (show all 616)
# Title Authors Year
1
Reinterpreting minimum inhibitory concentration (MIC) data of itraconazole versus terbinafine for dermatophytosis - time to look beyond the MIC data? ( 29243676 )
2018
2
Severe dermatophytosis in solid organ transplant recipients: A French retrospective series and literature review. ( 29094463 )
2018
3
Comparison of real-time PCR with fungal culture for the diagnosis of Microsporum canis dermatophytosis in shelter cats: a field study. ( 29172910 )
2018
4
Cellular immunodeficiency related to chronic dermatophytosis in a patient with Schistosoma mansoni infection: can schistosomiasis induce immunodeficiency? ( 28327819 )
2017
5
Diagnosis and treatment of dermatophytosis in dogs and cats.: Clinical Consensus Guidelines of the World Association for Veterinary Dermatology. ( 28516493 )
2017
6
Dermatophytosis: Fighting the Challenge: Conference Proceedings and Learning Points. September 2-3, 2017, PGIMER, Chandigarh, India. ( 29204417 )
2017
7
Diagnosis of Dermatophytosis by Conventional Methods and Comparatative analysis of Sabouraud Dextrose Agar and Dermatophyte Test Medium for Isolation of Dermatophytes. ( 28588164 )
2017
8
Deep Dermatophytosis Caused by Zoophilic Strain ofA Trichophyton interdigitaleA with Successful Treatment of Itraconazole. ( 28154954 )
2017
9
Recurrent dermatophytosis: A rising problem in Sikkim, a Himalayan state of India. ( 29323069 )
2017
10
Isotretinoin may affect pharmacokinetics of itraconazole in the skin: Is it rational to combine both for the treatment of dermatophytosis? ( 27853005 )
2017
11
Clinical evaluation of I^-tubulin real-time PCR for rapid diagnosis of dermatophytosis, a comparison with mycological methods. ( 28699277 )
2017
12
Dermatophytes and dermatophytosis in the eastern and southern parts of Africa. ( 28419352 )
2017
13
Comment on: "A Unique Clinicopathological Manifestation of Fungal Infection: A Case Series of Deep Dermatophytosis in Immunosuppressed Patients". ( 28653140 )
2017
14
DIAGNOSIS AND SUCCESSFUL TREATMENT OF A POTENTIALLY ZOONOTIC DERMATOPHYTOSIS CAUSED BY MICROSPORUM GYPSEUM IN A ZOO-HOUSED NORTH AMERICAN PORCUPINE (ERETHIZON DORSATUM). ( 28749293 )
2017
15
The menace of dermatophytosis in India: The evidence that we need. ( 28366915 )
2017
16
Treatment of Dermatophytosis in Elderly, Children, and Pregnant Women. ( 28979861 )
2017
17
Use of a commercial qPCR assay in 52 high risk shelter cats for disease identification of dermatophytosis and mycological cure. ( 28833730 )
2017
18
Topical nitric oxide releasing nanoparticles are effective in a murine model of dermal Trichophyton rubrum dermatophytosis. ( 28712918 )
2017
19
Development of enzyme immunoassays (ELISA and Western blot) for the serological diagnosis of dermatophytosis in symptomatic and asymptomatic cats. ( 28340215 )
2017
20
Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis. ( 28794551 )
2017
21
<i>In Vivo</i> Evaluation of<i>Galla chinensis</i>Solution in the Topical Treatment of Dermatophytosis. ( 29259645 )
2017
22
Epidemiological status of dermatophytosis in Guilan, north of Iran. ( 29302626 )
2017
23
Intracutaneous pharmacokinetics of oral antifungals and their relevance in recalcitrant cutaneous dermatophytosis: Time to revisit basics. ( 28936991 )
2017
24
Trichophyton rubrum tinea capitis in an HIV-positive patient with generalized dermatophytosis. ( 28050591 )
2017
25
Relationship Between Phenotypic and Genotypic Characteristics of Trichophyton mentagrophytes Strains Isolated from Patients with Dermatophytosis. ( 28101694 )
2017
26
Rational for Drug Dosimetry and Duration of Terbinafine in the Context of Recalcitrant Dermatophytosis: Is 500 mg Better than 250 mg OD or BD? ( 29263545 )
2017
27
An invertebrate infection model for evaluating anti-fungal agents against dermatophytosis. ( 28947778 )
2017
28
Transcriptome analysis of Trichophyton mentagrophytes-induced rabbit (Oryctolagus cuniculus) dermatophytosis. ( 29225090 )
2017
29
The Great Indian Epidemic of Superficial Dermatophytosis: An Appraisal. ( 28584364 )
2017
30
Correlation between histopathologic features and likelihood of identifying superficial dermatophytosis with periodic acid Schiff-diastase staining: a cohort study. ( 27859475 )
2017
31
A Unique Clinicopathological Manifestation of Fungal Infection: A Case Series of Deep Dermatophytosis in Immunosuppressed Patients. ( 28389891 )
2017
32
Are Th17 Cells Playing a Role in Immunity to Dermatophytosis? ( 27878642 )
2016
33
Diagnosis of Dermatophytosis Using Molecular Biology. ( 27480761 )
2016
34
Clinical application of a molecular assay for the detection of dermatophytosis and a novel non-invasive sampling technique. ( 27780596 )
2016
35
Efficacy of pomades containing different percentages of enilconazole in the treatment of bovine dermatophytosis. ( 26990840 )
2016
36
'Ring-within-a-ring' appearance: morphological clue to topical steroid abuse in dermatophytosis. ( 26856975 )
2016
37
Evaluation of the Efficacy of ME1111 in the Topical Treatment of Dermatophytosis in a Guinea Pig Model. ( 26833160 )
2016
38
The Use of Adhesive Tapes to Transfer Skin-scrapings for Sequential Laboratory Diagnosis of Dermatophytosis. ( 26936345 )
2016
39
Dermatophytosis: fluorostaining enhances speed and sensitivity in direct microscopy of skin, nail and hair specimens from dermatology outpatients. ( 26931645 )
2016
40
Dermatophytosis in northern Africa. ( 26692117 )
2016
41
Progredient dermatophytosis and nevus anemicus: aA pathogenetic mediated relationship. ( 27577247 )
2016
42
Epidemiological trends of dermatophytosis in Tehran, Iran: A five-year retrospective study. ( 27520535 )
2016
43
Relapse after Oral Terbinafine Therapy in Dermatophytosis: A Clinical and Mycological Study. ( 27688443 )
2016
44
The menace of chronic and recurrent dermatophytosis in India: Is the problem deeper than we perceive? ( 27057485 )
2016
45
Clinico-microbiological study of dermatophytosis in a tertiary-care hospital in North Karnataka. ( 27559499 )
2016
46
Fluorescence Microscopy as a Diagnostic Tool for Dermatophytosis. ( 26894772 )
2016
47
Epidemiological Aspects of Dermatophytosis in Khuzestan, southwestern Iran, an Update. ( 26886443 )
2016
48
Dermatophyte abscesses caused by Trichophyton rubrum in a patient without pre-existing superficial dermatophytosis: a case report. ( 27317023 )
2016
49
Dermatophytosis in donkeys (Equus asinus) due to Microsporum racemosum, an unusual geophilic agent. ( 27453813 )
2016
50
Efficacy of Topical Therapy with Newly Developed Terbinafine and Econazole Formulations in the Treatment of Dermatophytosis in Cats. ( 27760032 )
2016

Variations for Dermatophytosis

Expression for Dermatophytosis

Search GEO for disease gene expression data for Dermatophytosis.

Pathways for Dermatophytosis

Pathways related to Dermatophytosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10 ADGRL1 ADGRL2

GO Terms for Dermatophytosis

Biological processes related to Dermatophytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response to Gram-negative bacterium GO:0050829 9.26 DEFB4A LTF
2 antimicrobial humoral response GO:0019730 9.16 DEFB4A LTF
3 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 8.96 DEFB4A LTF
4 killing of cells of other organism GO:0031640 8.62 DEFB4A LTF

Molecular functions related to Dermatophytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 latrotoxin receptor activity GO:0016524 8.62 ADGRL1 ADGRL2

Sources for Dermatophytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....